Recently, a Mendelian Randomization analysis that systematically screened 41 cytokines identified that CCL2 was significantly associated with an increased risk of overall breast cancer, as well as ER-positive breast cancer (10). This evidence concerns the gene CCL2 and breast carcinoma.